Yuhan Corporation Receives KRW 43.2 Billion Milestone Royalty for 'Rayzertinib'
[Asia Economy Reporter Kum Boryeong] Yuhan Corporation announced on the 8th that it is expected to receive a technology fee of 35 million USD (approximately 43.2 billion KRW) following the achievement of milestone payments for the EGFR-targeted anticancer drug 'Lazertinib,' which was licensed out to Janssen Biotech, Inc.
Hot Picks Today
"Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Lotte Pays Deposit First, Daewoo Responds: Seongsu District 4 Construction Rights Rematch [Real Estate AtoZ]
- Despite ‘Tank Day’ Controversy, Gwangju Schools Purchased Starbucks Gift Certificates
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
This amount corresponds to more than 2.5% of Yuhan Corporation's consolidated equity capital.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
